A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
NCT06925542
This study is recruiting at 7 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- SLE (Systemic Lupus)
- Lupus Erythematosus, Systemic
- Lupus Nephritis
- Systemic Sclerosis
- Inflammatory Myopathy, Idiopathic
- Myositis
- Diffuse Cutaneous Systemic Sclerosis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- CRISPR Therapeutics
- Last updated on ClinicalTrials.gov
- August 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Stanford University Medical Center · Redwood City, CA
Illinois · 1
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center · Chicago, IL
Iowa · 1
- University of Iowa · Iowa City, IA
Louisiana · 1
- Tulane University Medical Center · New Orleans, LA
Massachusetts · 1
- Boston Medical Center · Boston, MA
Missouri · 1
- Washington University School of Medicine · St Louis, MO
North Carolina · 1
- University of North Carolina TraCS Institute - CTRC · Chapel Hill, NC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.